ABBV Mar 2024 175.000 put
| Previous close | 41.95 |
| Open | 41.80 |
| Bid | 23.25 |
| Ask | 24.05 |
| Strike | 175.00 |
| Expiry date | 2024-03-15 |
| Day's range | 41.80 - 41.95 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksAbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
AbbVie (ABBV) closed at $154.65 in the latest trading session, marking a +1.25% move from the prior day.
PR NewswireAbbVie Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma
AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has granted conditional marketing authorization for TEPKINLY® (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. TEPKINLY is the first and only subcutaneous T-cell engaging bispecific antibody approved for the treatment of this patient population in the European Union (EU), as well as Liechtenste
Motley Fool3 Bargain Stocks to Buy in a Market That's Priced for Perfection
Stock valuations are at historically high levels. Three Motley Fool contributors identified bargain stocks to buy in a market that's priced for perfection. Here's why they picked AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE).
